STIM übertreffen die 17 der letzten 30Schätzungen.
57%
Nächster Bericht
Datum des nächsten Berichts
02. März 2026
Estimate forQ4 25(Revenue/ EPS)
$41.48M
/
-$0.10
Implizierte Änderung vonQ3 25(Revenue/ EPS)
+11.22%
/
-23.08%
Implizierte Änderung vonQ4 24(Revenue/ EPS)
+84.41%
/
-69.70%
Neuronetics, Inc. Common Stock earnings per share and revenue
On 04. Nov. 2025, STIM reported earnings of -0.13 USD per share (EPS) for Q3 25, missing the estimate of -0.12 USD, resulting in a -0.62% surprise. Revenue reached 37.30 million, compared to an expected 38.60 million, with a -3.38% difference. The market reacted with a +3.61% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analysts forecast an EPS of -0.10 USD, with revenue projected to reach 41.48 million USD, implying an decrease of -23.08% EPS, and increase of 11.22% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AngioDynamics, Inc.
Report Date
06. Jan. 2026 For Q2 26
Estimate
-$0.10
Aktuell
$0.00
Überraschung
+100.00%
FAQ
What were Neuronetics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Neuronetics, Inc. Common Stock reported EPS of -$0.13, missing estimates by -0.62%, and revenue of $37.30M, -3.38% below expectations.
How did the market react to Neuronetics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 3.61%, changed from $2.77 before the earnings release to $2.87 the day after.
When is Neuronetics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 02. März 2026.
What are the forecasts for Neuronetics, Inc. Common Stock's next earnings report?
Based on 5
analysts, Neuronetics, Inc. Common Stock is expected to report EPS of -$0.10 and revenue of $41.48M for Q4 2025.